After-Hours Movers 09/29: Nike, Micron Fall Post Earnings

Amylyx Pharmaceuticals (AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ

Amylyx Pharmaceuticals (NASDAQ: AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ

Nike (NKE) PT Lowered to $114 at Cowen

Cowen analyst John Kernan lowered the price target on Nike (NYSE: NKE) to $114.00 (from $127.00) while maintaining a Outperform rating following earnings.

The analyst commented, "Nike is showing strength from a top-line perspective, and we think China could return to growth by Q2, but... More

Nike (NKE) PT Lowered to $115 at Jefferies

Jefferies analyst Randal Konik lowered the price target on Nike (NYSE: NKE) to $115.00 (from $130.00) while maintaining a Buy rating.

Amylyx Pharmaceuticals (AMLX) Confirms FDA Approval of RELYVRIO for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic lateral sclerosis (ALS). RELYVRIO (previously known as AMX0035 in the U.S.) significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. RELYVRIO can be taken as a monotherapy or with existing approved treatments.

Todays FDA approval of RELYVRIO is an exciting milestone for the ALS community and is a major step... More

Micron Technology (MU) PT Lowered to $70 at BMO Capital

BMO Capital analyst Ambrish Srivastava lowered the price target on Micron Technology (NASDAQ: MU) to $70.00 (from $80.00) while maintaining a Outperform rating following earnings.

The analyst commented, "We said heading into earnings that our thesis will be put to a severe test... More